According to a report by Yahoo Finance on October 20, Philip Morris International (PMI) has submitted a Pre-Market Tobacco Product Application (PMTA) and a Modified Risk Tobacco Product Application (MRTPA) to the US Food and Drug Administration (FDA) for its IQOS ILUMA heated tobacco product.
In order to sell their new tobacco products in the United States, PMI needs to obtain PMTA approval. The company is also seeking permission to market the IQOS ILUMA product as an improved risk product that reduces exposure to harmful and potentially harmful chemicals, just like the previous versions of IQOS which were granted this status.
The following are the key details released by PMI:
Unlike traditional cigarettes, IQOS products heat but do not burn tobacco. The IQOS ILUMA product is the most innovative heated tobacco product from PMI. In comparison to the previously FDA authorized versions of IQOS, they show a significant reduction in the formation of harmful and potentially harmful constituents. IQOS ILUMA demonstrates higher overall conversion rates and improved consumer satisfaction among adult smokers in various countries worldwide. This product relies on a completely different heating technology from previous versions of IQOS and includes several technological advancements, such as improved device and battery life. IQOS ILUMA is currently available in 27 international markets. PMI's application is supported by thorough scientific evaluations, including aerosol chemistry, in vitro toxicology, pharmacokinetic studies, consumer perception and behavior research, and comprehensive scientific data collected from the previous version of the IQOS system. The IQOS ILUMA device operates on the SMARTCORE induction system, which internally heats tobacco through the use of TEREA SMARTCORE pods designed exclusively for use with the IQOS ILUMA device. PMI has submitted applications for three ILUMA devices and five pods: TEREA BLUE, TEREA GREEN, TEREA SIENNA, TEREA BRONZE, and TEREA AMBER.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
